Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.41 USD
Change Today +0.06 / 4.44%
Volume 1.9M
GALE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

galena biopharma inc (GALE) Snapshot

Open
$1.41
Previous Close
$1.35
Day High
$1.43
Day Low
$1.36
52 Week High
06/11/14 - $3.58
52 Week Low
03/13/15 - $1.33
Market Cap
216.9M
Average Volume 10 Days
3.8M
EPS TTM
$-0.31
Shares Outstanding
153.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALENA BIOPHARMA INC (GALE)

Related News

No related news articles were found.

galena biopharma inc (GALE) Related Businessweek News

No Related Businessweek News Found

galena biopharma inc (GALE) Details

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company’s lead product candidate comprise NeuVax (nelipepimut-S), which is in Phase III clinical trials for use in the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin that is used for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with Herceptin for use in HER2 gene-amplified breast cancer treatment. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials that is used for the prevention of recurrence in patients with ovarian and endometrial cancers; and GALE-401 (anagrelide controlled release), which has completed Phase I clinical trials that is used for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Portland, Oregon.

57 Employees
Last Reported Date: 03/5/15
Founded in 2003

galena biopharma inc (GALE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $490.0K
Chief Financial Officer, Vice President and C...
Total Annual Compensation: $236.0K
Compensation as of Fiscal Year 2013.

galena biopharma inc (GALE) Key Developments

Galena Biopharma, Inc. Announces Human Leukocyte Antigen (HLA) - A24+ or HLA-A26+ Women Now Eligible for Enrollment into the Ongoing Phase 2B Clinical Trial with Neuvax (Nelipepimut-S) in Combination with Trastuzumab

Galena Biopharma, Inc. announced that human leukocyte antigen (HLA) - A24+ or HLA-A26+ women are now eligible for enrollment into the ongoing Phase 2b clinical trial with NeuVax (nelipepimut-S) in combination with trastuzumab (Herceptin®; Genentech/Roche). The trial evaluates node positive and triple negative, node negative breast cancer patients with immunohistochemistry (IHC) HER2 1+/2+ expressing tumors who are disease-free after standard of care therapy. The nelipepimut-S peptide works by binding to specific HLA proteins, or molecules key to immunological activity and are involved in the induction of protective T-cell immune responses. To date, NeuVax has been tested in trials with patients who are HLA-A2+ or A3+, representing more than 60% of the North American, European and Chinese populations. NeuVax has also been shown to bind to HLA-A24 and A26, which represents an additional 10-15% of the population in the U.S., but more importantly, represents up to approximately 70% of the population in Japan. NeuVax (nelipepimut-S) is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. It is the monodominant peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. NeuVax has been shown to bind to HLA-A2 and A3, as well as HLA-A24 and A26 molecules. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to specific HLA molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut-S immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. In addition to the Phase 2b trial in node positive and triple negative HER2 IHC 1+/2+ patients (clinicaltrials.gov identifier: NCT01570036), NeuVax is currently in an international, Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTreatment) study under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA).

Galena Biopharma Mulls Acquisition

Galena Biopharma, Inc. (NasdaqCM:GALE) is seeking acquisition. Galena Biopharma said in Sec filling about use of proceed from composite units offerings, “General corporate purposes may include repayment of our existing long-term debt, capital expenditures, milestone payments under our existing license and other agreements and payments in connection with possible future acquisitions and strategic investments."

Galena Biopharma, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 10:00 AM

Galena Biopharma, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 10:00 AM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALE:US $1.41 USD +0.06

GALE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.79 AUD +0.04
BioDelivery Sciences International Inc $10.51 USD -3.38
Regulus Therapeutics Inc $17.26 USD +0.44
Silence Therapeutics PLC 282.00 GBp +1.00
View Industry Companies
 

Industry Analysis

GALE

Industry Average

Valuation GALE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.8x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENA BIOPHARMA INC, please visit www.galenabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.